TimeScale Financial’s Arbutus Biopharma ABUS Stock Holding History

TimeScale Financial’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$690	Hold	300	–	–	﹤0.01%	560
2023 Q1	$909	Hold	300	–	–	﹤0.01%	539
2022 Q4	$573	Hold	300	–	–	﹤0.01%	532
2022 Q3	$1K	Hold	300	–	–	﹤0.01%	478
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	447
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	469
2021 Q4	$1K	Hold	300	–	–	﹤0.01%	465
2021 Q3	$1K	Hold	300	–	–	﹤0.01%	456
2021 Q2	$1K	Hold	300	–	–	﹤0.01%	457
2021 Q1	$1K	Hold	300	–	–	﹤0.01%	451
2020 Q4	$1K	Hold	300	–	–	﹤0.01%	391
2020 Q3	$1K	Hold	300	–	–	﹤0.01%	413
2020 Q2	$1K	Hold	300	–	–	﹤0.01%	405
2020 Q1	$0	Hold	300	–	–	﹤0.01%	404
2019 Q4	$0	Hold	300	–	–	﹤0.01%	503
2019 Q3	$0	Hold	300	–	–	﹤0.01%	494
2019 Q2	$1K	Buy	+300	New	+$767	﹤0.01%	467

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TimeScale Financial's ABUS Position: Q2 2023 in Review

TimeScale Financial held its Arbutus Biopharma (ABUS) position steady in Q2 2023 at 300 shares worth $690. The position accounts for ﹤0.01% of the portfolio, ranked #560.

TimeScale Financial first reported a position in ABUS in Q2 2019 and has held it in 17 quarters since. The position peaked at $1K in Q3 2022. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

TimeScale Financial held 300 shares of Arbutus Biopharma worth $690 as of Q2 2023.
TimeScale Financial left its Arbutus Biopharma share count unchanged in Q2 2023.
Arbutus Biopharma made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #560 holding.
TimeScale Financial first reported a position in Arbutus Biopharma in Q2 2019 and has held it in 17 quarters since.
TimeScale Financial's Arbutus Biopharma position peaked at $1K in Q3 2022.
111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.